ACB Stock Chart & Stats
$4.01
$0.07(2.62%)
At close: 4:00 PM EDT
$4.01
$0.07(2.62%)
Day’s Range― - ―
52-Week Range$2.56 - $6.67
Previous Close$2.73
Volume1.41M
Average Volume (3M)908.85K
Market Cap
$253.71M
Enterprise Value$117.20M
Total Cash (Recent Filing)$149.12M
Total Debt (Recent Filing)$22.68M
Price to Earnings (P/E)―
Beta1.09
Next Earnings
Nov 11, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.93
Shares Outstanding64,841,500
10 Day Avg. Volume857,036
30 Day Avg. Volume908,845
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.51
Price to Sales (P/S)0.81
P/FCF Ratio-7.20
Enterprise Value/Market Cap0.46
Enterprise Value/Revenue0.41
Enterprise Value/Gross Profit1.19
Enterprise Value/Ebitda-0.65
Forecast
1Y Price Target
$4.21Price Target Upside4.92% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.3
Revenue Forecast (FY)$212.05M
Bulls Say, Bears Say
Bulls Say
International Medical GrowthInternational medical growth and a rising share of revenue generated outside Canada strengthen Aurora’s geographic diversification. Expansion in Germany and other regulated markets can support more durable demand, reduce reliance on Canadian conditions, and improve the company’s growth platform.
Strong Gross MarginA 58% adjusted gross margin, supported by higher-margin international sales, indicates that Aurora’s product mix and market positioning can generate attractive economics. Sustaining this level would improve operating leverage and provide a stronger foundation for future EBITDA growth.
Low-leverage Balance SheetSubstantial liquidity and zero debt give Aurora financial flexibility to fund international expansion, capacity investments, or acquisitions without immediate refinancing pressure. This balance-sheet strength also provides resilience while the company works through operating volatility and market changes.
Bears Say
Declining Revenue And LossesFalling trailing revenue and continued operating and net losses show that Aurora has not yet established a stable earnings base. Volatility between annual periods makes the turnaround less predictable and could limit internally funded investment until profitability becomes more consistent.
Persistent Cash BurnNegative operating and free cash flow indicate that the business currently consumes cash despite its strong liquidity position. If cash generation does not improve, Aurora may have less flexibility for growth initiatives and greater dependence on balance-sheet resources over coming quarters.
Canadian Reimbursement PressureThe reimbursement reduction is a structural pressure on Canadian medical revenue and adjusted gross profit rather than a temporary trading issue. Lower realized economics in that market can weigh on consolidated profitability and increase Aurora’s reliance on international growth to offset the impact.
Aurora Cannabis News
ACB FAQ
What was Aurora Cannabis’s price range in the past 12 months?
Aurora Cannabis lowest stock price was $2.56 and its highest was $6.67 in the past 12 months.
What is Aurora Cannabis’s market cap?
Aurora Cannabis’s market cap is $253.71M.
When is Aurora Cannabis’s upcoming earnings report date?
Aurora Cannabis’s upcoming earnings report date is Nov 11, 2026 which is in 35 days.
How were Aurora Cannabis’s earnings last quarter?
Aurora Cannabis released its earnings results on Aug 05, 2026. The company reported -$0.049 earnings per share for the quarter, beating the consensus estimate of -$0.129 by $0.079.
Is Aurora Cannabis overvalued?
According to Wall Street analysts Aurora Cannabis’s price is currently Undervalued.
Does Aurora Cannabis pay dividends?
Aurora Cannabis does not currently pay dividends.
What is Aurora Cannabis’s EPS estimate?
Aurora Cannabis’s EPS estimate is -0.05.
How many shares outstanding does Aurora Cannabis have?
Aurora Cannabis has 64,841,500 shares outstanding.
What happened to Aurora Cannabis’s price movement after its last earnings report?
Aurora Cannabis reported an EPS of -$0.049 in its last earnings report, beating expectations of -$0.129. Following the earnings report the stock price went up 3.559%.
Which hedge fund is a major shareholder of Aurora Cannabis?
Currently, no hedge funds are holding shares in ACB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Aurora Cannabis Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.21 (4.92% Upside)
$4.21 (4.92% Upside)
Blogger Sentiment
Bullish
ACB Sentiment 88%
Sector Average 66%
Sector Average 66%
Crowd Wisdom
Positive
Last 7 Days ▲ 1.0%
Last 30 Days ▲ 0.5%
Last 30 Days ▲ 0.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-21.06%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-28.73%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Aurora Cannabis
Aurora Cannabis Inc. is a Canada-based firm specializing in the cultivation, processing, and global distribution of cannabis and its various derivative products. The company's operations encompass a broad spectrum of the cannabis industry, from facility engineering and design to genetic research, production, and the development of new products, all supported by extensive wholesale and retail networks. For medical users, Aurora offers diverse strains of dried cannabis, oils, capsules, and topical kits. Additionally, it markets a range of accessories, including vaporizers, consumable parts, herb mills (specifically for CanniMed products), grinders, and lockable vaporizer containers. The company is committed to advancing medical cannabis, with ongoing development across oral, topical, edible, and inhalable product categories. Aurora also provides key services such as patient counseling, design and construction assistance, and comprehensive analytical product testing for cannabis, alongside operating CanvasRX, a network dedicated to cannabis counseling and outreach. Its expansive brand family includes Aurora, Aurora Drift, San Rafael '71, Daily Special, AltaVie, MedReleaf, CanniMed, Whistler, Woodstock, and WMMC. The corporate headquarters are located in Edmonton, Canada.
ACB Company Deck
ACB Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presents a balanced picture: material short-term financial headwinds (notably a large year-over-year decline in adjusted EBITDA, lower adjusted net income, and negative free cash flow) driven largely by an external 30% reimbursement cut in Canadian medical. Offsetting these negatives are clear strategic strengths—17% international revenue growth to $43M, a 58% adjusted gross margin, strong cash position with no debt, an accretive EU GMP acquisition (Safari), genetics-driven production advantages (up to 40% yield improvement), and market leadership in several regulated international markets. Management frames FY2027 as a transitionary year with expected sequential improvement in Q2 and reiterated long-term targets (sustained double-digit growth and superior margins). Given the mix of significant near-term financial declines and pronounced strategic/operational positives, the overall tone is balanced.View all ACB earnings summariesACB Stock 12 Month Forecast
Average Price Target
$4.21
▲(4.92% Upside)
Technical Analysis
Ownership Overview
0.59% Insiders
0.07% Mutual Funds
<0.01% Other Institutional Investors
95.63% Public Companies and
Individual Investors